Paclitaxel and carboplatin with simultaneous thoracic irradiation in regionally advanced non-small cell lung cancer

Chandra Belani, J. Aisner, R. Ramanathan, J. Jett, J. Greenberger, R. Day, M. J. Capazolli, D. Hiponia, C. Engstrom

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Sequential chemoradiotherapy has been used repeatedly in the treatment of patients with advanced, unresectable non-small cell lung cancer. Studies by the Cancer and Leukemia Group B, the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group, and European investigators demonstrate superior survival results for combined-modality therapy over radiotherapy alone. Based on these results end on our previous work with carboplatin end standard daily thoracic radiotherapy, a phase II study was designed to incorporate radiosensitizing paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) doses into the carboplatin/radiotherapy regimen to improve the therapeutic index and define the toxicities. Eligible patients had histologically confirmed, regionally advanced, unresectable non-small cell lung cancer and were not allowed to have received prior chemoradiotherapy. During 6 to 7 weeks of treatment, peclitaxel 45 mg/m2/wk was administered over 3 hours before carboplatin 100 mg/m2/wk. Thoracic radiotherapy was given 5 days per week in 1.8-Gy fractions throughout the treatment period, for a total dose of 60 to 65 Gy. No grade 4 toxicities were noted among the 32 patients enrolled. Seven patients had chemotherapy doses delayed for grade 3 neutropenia, and one patient had grade 3 mucositis/esophagitis that required hospitalization. Two deaths during the study were attributed to rapidly progressive disease. Median survival has not yet been reached, and all patients are being observed for patterns of response end survival. These preliminary data demonstrate the feasibility of combined paclitaxel, carboplatin, and simultaneous thoracic irradiation with acceptable toxicities. The regimen appears promising in regionally advanced non-small cell lung cancer end should be incorporated in future randomized studies. Additionally, full-dose induction chemotherapy regimens to maximize the systemic effects followed by simultaneous chemoradiotherapy require evaluation in future studies.

Original languageEnglish (US)
JournalSeminars in Radiation Oncology
Volume7
Issue number2 SUPPL. 1
StatePublished - Jun 25 1997

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Thorax
Radiotherapy
Chemoradiotherapy
Survival
Combined Modality Therapy
Mucositis
Radiation Oncology
Induction Chemotherapy
Esophagitis
Therapeutics
Group Psychotherapy
Neutropenia
Leukemia
Hospitalization
Research Personnel
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Belani, C., Aisner, J., Ramanathan, R., Jett, J., Greenberger, J., Day, R., ... Engstrom, C. (1997). Paclitaxel and carboplatin with simultaneous thoracic irradiation in regionally advanced non-small cell lung cancer. Seminars in Radiation Oncology, 7(2 SUPPL. 1).
Belani, Chandra ; Aisner, J. ; Ramanathan, R. ; Jett, J. ; Greenberger, J. ; Day, R. ; Capazolli, M. J. ; Hiponia, D. ; Engstrom, C. / Paclitaxel and carboplatin with simultaneous thoracic irradiation in regionally advanced non-small cell lung cancer. In: Seminars in Radiation Oncology. 1997 ; Vol. 7, No. 2 SUPPL. 1.
@article{760a05e1f6384a7e8a282ee65c265dd1,
title = "Paclitaxel and carboplatin with simultaneous thoracic irradiation in regionally advanced non-small cell lung cancer",
abstract = "Sequential chemoradiotherapy has been used repeatedly in the treatment of patients with advanced, unresectable non-small cell lung cancer. Studies by the Cancer and Leukemia Group B, the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group, and European investigators demonstrate superior survival results for combined-modality therapy over radiotherapy alone. Based on these results end on our previous work with carboplatin end standard daily thoracic radiotherapy, a phase II study was designed to incorporate radiosensitizing paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) doses into the carboplatin/radiotherapy regimen to improve the therapeutic index and define the toxicities. Eligible patients had histologically confirmed, regionally advanced, unresectable non-small cell lung cancer and were not allowed to have received prior chemoradiotherapy. During 6 to 7 weeks of treatment, peclitaxel 45 mg/m2/wk was administered over 3 hours before carboplatin 100 mg/m2/wk. Thoracic radiotherapy was given 5 days per week in 1.8-Gy fractions throughout the treatment period, for a total dose of 60 to 65 Gy. No grade 4 toxicities were noted among the 32 patients enrolled. Seven patients had chemotherapy doses delayed for grade 3 neutropenia, and one patient had grade 3 mucositis/esophagitis that required hospitalization. Two deaths during the study were attributed to rapidly progressive disease. Median survival has not yet been reached, and all patients are being observed for patterns of response end survival. These preliminary data demonstrate the feasibility of combined paclitaxel, carboplatin, and simultaneous thoracic irradiation with acceptable toxicities. The regimen appears promising in regionally advanced non-small cell lung cancer end should be incorporated in future randomized studies. Additionally, full-dose induction chemotherapy regimens to maximize the systemic effects followed by simultaneous chemoradiotherapy require evaluation in future studies.",
author = "Chandra Belani and J. Aisner and R. Ramanathan and J. Jett and J. Greenberger and R. Day and Capazolli, {M. J.} and D. Hiponia and C. Engstrom",
year = "1997",
month = "6",
day = "25",
language = "English (US)",
volume = "7",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 1",

}

Belani, C, Aisner, J, Ramanathan, R, Jett, J, Greenberger, J, Day, R, Capazolli, MJ, Hiponia, D & Engstrom, C 1997, 'Paclitaxel and carboplatin with simultaneous thoracic irradiation in regionally advanced non-small cell lung cancer', Seminars in Radiation Oncology, vol. 7, no. 2 SUPPL. 1.

Paclitaxel and carboplatin with simultaneous thoracic irradiation in regionally advanced non-small cell lung cancer. / Belani, Chandra; Aisner, J.; Ramanathan, R.; Jett, J.; Greenberger, J.; Day, R.; Capazolli, M. J.; Hiponia, D.; Engstrom, C.

In: Seminars in Radiation Oncology, Vol. 7, No. 2 SUPPL. 1, 25.06.1997.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Paclitaxel and carboplatin with simultaneous thoracic irradiation in regionally advanced non-small cell lung cancer

AU - Belani, Chandra

AU - Aisner, J.

AU - Ramanathan, R.

AU - Jett, J.

AU - Greenberger, J.

AU - Day, R.

AU - Capazolli, M. J.

AU - Hiponia, D.

AU - Engstrom, C.

PY - 1997/6/25

Y1 - 1997/6/25

N2 - Sequential chemoradiotherapy has been used repeatedly in the treatment of patients with advanced, unresectable non-small cell lung cancer. Studies by the Cancer and Leukemia Group B, the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group, and European investigators demonstrate superior survival results for combined-modality therapy over radiotherapy alone. Based on these results end on our previous work with carboplatin end standard daily thoracic radiotherapy, a phase II study was designed to incorporate radiosensitizing paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) doses into the carboplatin/radiotherapy regimen to improve the therapeutic index and define the toxicities. Eligible patients had histologically confirmed, regionally advanced, unresectable non-small cell lung cancer and were not allowed to have received prior chemoradiotherapy. During 6 to 7 weeks of treatment, peclitaxel 45 mg/m2/wk was administered over 3 hours before carboplatin 100 mg/m2/wk. Thoracic radiotherapy was given 5 days per week in 1.8-Gy fractions throughout the treatment period, for a total dose of 60 to 65 Gy. No grade 4 toxicities were noted among the 32 patients enrolled. Seven patients had chemotherapy doses delayed for grade 3 neutropenia, and one patient had grade 3 mucositis/esophagitis that required hospitalization. Two deaths during the study were attributed to rapidly progressive disease. Median survival has not yet been reached, and all patients are being observed for patterns of response end survival. These preliminary data demonstrate the feasibility of combined paclitaxel, carboplatin, and simultaneous thoracic irradiation with acceptable toxicities. The regimen appears promising in regionally advanced non-small cell lung cancer end should be incorporated in future randomized studies. Additionally, full-dose induction chemotherapy regimens to maximize the systemic effects followed by simultaneous chemoradiotherapy require evaluation in future studies.

AB - Sequential chemoradiotherapy has been used repeatedly in the treatment of patients with advanced, unresectable non-small cell lung cancer. Studies by the Cancer and Leukemia Group B, the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group, and European investigators demonstrate superior survival results for combined-modality therapy over radiotherapy alone. Based on these results end on our previous work with carboplatin end standard daily thoracic radiotherapy, a phase II study was designed to incorporate radiosensitizing paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) doses into the carboplatin/radiotherapy regimen to improve the therapeutic index and define the toxicities. Eligible patients had histologically confirmed, regionally advanced, unresectable non-small cell lung cancer and were not allowed to have received prior chemoradiotherapy. During 6 to 7 weeks of treatment, peclitaxel 45 mg/m2/wk was administered over 3 hours before carboplatin 100 mg/m2/wk. Thoracic radiotherapy was given 5 days per week in 1.8-Gy fractions throughout the treatment period, for a total dose of 60 to 65 Gy. No grade 4 toxicities were noted among the 32 patients enrolled. Seven patients had chemotherapy doses delayed for grade 3 neutropenia, and one patient had grade 3 mucositis/esophagitis that required hospitalization. Two deaths during the study were attributed to rapidly progressive disease. Median survival has not yet been reached, and all patients are being observed for patterns of response end survival. These preliminary data demonstrate the feasibility of combined paclitaxel, carboplatin, and simultaneous thoracic irradiation with acceptable toxicities. The regimen appears promising in regionally advanced non-small cell lung cancer end should be incorporated in future randomized studies. Additionally, full-dose induction chemotherapy regimens to maximize the systemic effects followed by simultaneous chemoradiotherapy require evaluation in future studies.

UR - http://www.scopus.com/inward/record.url?scp=0031009425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031009425&partnerID=8YFLogxK

M3 - Article

VL - 7

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 2 SUPPL. 1

ER -